AmerisourceBergen is the second-largest distributor of pharmaceuticals in the U.S. As such, it’s subject to many of the same forces affecting McKesson, its top competitor. Branded drug price deflation and fewer expected new drug launches continue to put pressure on industry profits, and AmerisourceBergen has been working to counter those effects. The company was founded in 1985 and is headquartered in Chesterbrook, Penn.
Company Info
| CEO | Steven H. Collis |
| CEO Title | Chairman, President & Chief Executive Officer |
| Sector | Wholesalers |
| Industry | Wholesalers: Health Care |
| HQ Location | Chesterbrook, PA |
| Website | www.amerisourcebergen.com |
| Years on Fortune 500 List | 23 |
| Employees | 18,500 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $146,850 |
| Profits ($M) | $1,427.9 |
| Assets ($M) | $33,656 |
| Total Stockholder Equity ($M) | $2,129 |
| Market Value — as of March 31, 2017 ($M) | $19,229 |
Profit Ratios
| Profit as % of Revenues | 1% |
| Profits as % of Assets | 4.2% |
| Profits as % of Stockholder Equity | 67.1% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 632 |
| EPS % Change (from 2015) | - |
| EPS % Change (5 year annual rate) | 20% |
| EPS % Change (10 year annual rate) | 18.8% |
Total Return
| Total Return to Investors (2016) | -23.3% |
| Total Return to Investors (5 year, annualized) | 17.7% |
| Total Return to Investors (10 year, annualized) | 15% |
